Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens

1985 ◽  
Vol 21 (2) ◽  
pp. 204-216 ◽  
Author(s):  
B. de Muralt ◽  
N. de Tribolet ◽  
A.-C. Diserens ◽  
D. Stavrou ◽  
J.-P. Mach ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Human Gliomas ◽  
Hla Dr ◽  
Neuroectodermal Tumors

Therapy of Neuroectodermal Tumors with Monoclonal Antibodies

1990 ◽  
pp. 467-474
Author(s):  
W. G. Dippold ◽  
K. H. Meyer zum Büschenfelde
Keyword(s):  
Monoclonal Antibodies ◽  
Neuroectodermal Tumors

scholarly journals Heterogeneity in a lymphoid tumor: coexpression of T and B surface markers

Blood ◽  
1982 ◽  
Vol 60 (2) ◽  
pp. 373-380 ◽  
Author(s):  
RW Schroff ◽  
KA Foon
Keyword(s):  
Monoclonal Antibodies ◽  
T Cell ◽  
B Cell ◽  
Progenitor Cell ◽  
Leukemic Cells ◽  
Cytotoxic T Cell ◽  
Surface Markers ◽  
Lymphoid Tumor ◽  
Surface Immunoglobulin ◽  
Hla Dr

Abstract Heterogeneity of leukemic cells was defined in a case of lymphoma. Four phenotypically distinct subpopulations of leukemic cells were identified. One subpopulation was observed to simultaneously express B- and T-cell characteristics. B-cell characteristics included monoclonal IgM (lambda) surface immunoglobulin, HLA-DR antigens, and expression of the B-cell antigen identified by the BA-1 monoclonal antibody. T-cell characteristics included E-rosette formation, expression of the pan-T- associated antigens recognized by the Leu-1 and OKT-11 monoclonal antibodies, and expression of the suppressor cytotoxic T-cell- associated antigen recognized by the Leu-2 and OKT-8 monoclonal antibodies. In addition to this subpopulation, three other phenotypically distinct subpopulations were identified, two of which expressed monoclonal IgM (lambda) surface immunoglobulin. The results of this investigation indicates that three phenotypically distinct lymphoid subpopulations bearing B-cell characteristics, and probably a fourth T-cell subgroup, were derived from a common lineage. These findings suggest that the malignancy involved a lymphoid progenitor cell that may possess diverse maturational capacity.

HLA-DR expression on monocytes as a prognostic criterion for the development of pyoinflammatory processes at various stages of surgical treatment

2016 ◽  
Vol 94 (5) ◽  
pp. 379-382
Author(s):  
Mariya V. Chepeleva
Keyword(s):  
Monoclonal Antibodies ◽  
Surgical Treatment ◽  
Periprosthetic Infection ◽  
Relative Content ◽  
Immune Disorders ◽  
Flow Cytofluorometry ◽  
Posttraumatic Osteomyelitis ◽  
Hla Dr ◽  
Prognostic Criterion ◽  
Tubular Bones

We studied relative content of CD14+HLA-DR in 214 patients including those with aseptic instability and stable implants of the knee and the hip, periprosthetic infection of the hip, chronic posttraumatic osteomyelitis of long tubular bones, and osteomyelitis generalization (sepsis). We determined HLA-DR expression on monocytes by laser flow cytofluorometry using Beckman Coulter Epics XL (USA) cytometer and monoclonal antibodies (Immunotech Company, France). It has been demonstrated, that the decrease in HLA-DR expression on monocytes can be one of the mechanisms of increasing immune disorders in patients with orthopedic pathology and monitoring HLA-DR monocytic expression can be used as a prognostic criterion of developing pyoinflammatory processes at the stages of surgical treatment.

scholarly journals Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Blood ◽  
2010 ◽  
Vol 115 (25) ◽  
pp. 5180-5190 ◽  
Author(s):  
Rhona Stein ◽  
Pankaj Gupta ◽  
Xiaochuan Chen ◽  
Thomas M. Cardillo ◽  
Richard R. Furman ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibody ◽  
Monoclonal Antibodies ◽  
Signaling Pathways ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Kinase Signaling ◽  
Jnk Signaling ◽  
Multiple Myeloma Cell ◽  
Hla Dr

Abstract A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lymphocytic leukemia (CLL) patient specimens, followed by evaluation of the effects of IMMU-114 on extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathways. HLA-DR was expressed on the majority of these cells at markedly higher levels than CD20, CD22, and CD74. IMMU-114 was toxic to mantle cell lymphoma, CLL, acute lymphoblastic leukemia, hairy cell leukemia, non-Hodgkin lymphoma (including rituximab-resistant), and multiple myeloma cell lines, and also patient CLL cells. IMMU-114 induced disease-free survival in tumor-bearing SCID mice with early-stage disease and in models that are relatively resistant to anti-CD20 monoclonal antibodies. Despite positive staining, acute myelogenous leukemic cells were not killed by IMMU-114. The ability of IMMU-114 to induce activation of ERK and JNK signaling correlated with cytotoxicity and differentiates the mechanism of action of IMMU-114 from monoclonal antibodies against CD20 and CD74. Thus, antigen expression is not sufficient for cytotoxicity; antibody-induced hyperactivation of ERK and JNK mitogen activated protein kinase signaling pathways are also required.

Isolation of B lymphocytes for HLA-DR typing using monoclonal antibodies

1986 ◽  
Vol 91 (2) ◽  
pp. 175-180
Author(s):  
Craig Bohnhoff ◽  
Tom Sawyer ◽  
Annette Blair ◽  
David Senitzer
Keyword(s):  
Monoclonal Antibodies ◽  
B Lymphocytes ◽  
Hla Dr
Sign in / Sign up

Export Citation Format

Share Document